Compare ALB & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALB | NBIX |
|---|---|---|
| Founded | 1994 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.4B |
| IPO Year | 1994 | 1996 |
| Metric | ALB | NBIX |
|---|---|---|
| Price | $126.51 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 19 |
| Target Price | $102.16 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 4.2M | 969.9K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | N/A | ★ 4.19 |
| Revenue | ★ $4,946,415,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $1.29 | $18.01 |
| P/E Ratio | ★ N/A | $37.10 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $49.43 | $84.23 |
| 52 Week High | $132.90 | $157.67 |
| Indicator | ALB | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 64.81 |
| Support Level | $117.61 | $150.26 |
| Resistance Level | $132.90 | $154.35 |
| Average True Range (ATR) | 6.16 | 4.16 |
| MACD | -0.42 | 1.07 |
| Stochastic Oscillator | 65.52 | 93.25 |
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.